If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
TREATMENT STRATEGIES
HEMATOLOGY
Volume 2 Issue 1
ISSN 2047-7600
• Angiogenesis
• Bone Marrow Failures
• Leukemia
• Multiple Myeloma
• Non-Hodgkin Lymphomas
• Relapsed/Refractory AML
• Von Willebrand Disease
Articles include:
Paroxysmal Nocturnal Hemoglobinuria
New Challenges in the Management of Diffuse Large
B-Cell Lymphoma
Checkpoint and DNA Repair Inhibition in Leukemias
The Use of Vorinostat in Multiple Myeloma – An Update
from ASH 2011
New Weapons and Strategies in the Battle Against
Relapsed Acute Myeloid Leukemia (AML)
Includes a review of the 53rd ASH
Annual Meeting and Exposition
TREANDA® is her chemo.
This is her therapy.
Single-agent TREANDA tripled median PFS in patients with CLL*
42%!.$! IS INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA #,,
%Fl
TREATMENT STRATEGIES HEMATOLOGY Volume 2 Issue 1
TREANDA® is her chemo. This is her therapy.
Single-agent TREANDA tripled median PFS in patien
Brief Summary of Prescribing Information INDICATI
Table 3: Non-Hematologic Adverse Reactions Occurr
C CAMBRIDGE RESEARCH CENTR
TREATMENT STRATEGIES HEMATOLOGY Treatment Stra
Pursuing new options for patients through THE S
CONTENTS... 07 11 13 15 31
59 63 68 74 79 85
EDITORIALADVISORY PANEL including... Monica Be
MOST PATIENTS WITH MULTIPLE MYELOMA STILL
Treatment Strategies - Foreword Foreword
CAMBRIDGERESEARCHCENTRE HE
53rd ASH Annual Meeting and Exposition
Treatment Strategies - Congress Review
Treatment Strategies - Congress Review Progress o
Treatment Strategies - Congress Review Telik An
Treatment Strategies - Congress Review AWARD HIGH
Treatment Strategies - Congress Review continued
Treatment Strategies - Congress Review Avila Th
Treatment Strategies - Congress Review
Treatment Strategies - Congress Review New Dat
Treatment Strategies - Congress Review continued
Treatment Strategies - Congress Review PROMISIN
Treatment Strategies - Congress Review
Treatment Strategies - Congress Review Genetic an
C CAMBRIDGE RESEARCH CENTR
Treatment Strategies - Congress Review Summary of
Treatment Strategies - Angiogenesis TIMP-2:
Treatment Strategies - Angiogenesis tumor-indu
involved reduction of the cognate tyrosine kinase
Treatment Strategies - Angiogenesis tumor grow
Itohara S: Reduced angiogenesis and tumor progres
Treatment Strategies - Bone Marrow Failures
AB Proliferation (fold) Apoptosis (%) +/3A
Treatment Strategies - Bone Marrow Failures p5
Treatment Strategies - Bone Marrow Failures DNA
Treatment Strategies - Bone Marrow Failures he
Treatment Strategies - Leukemia Checkpoint
Treatment Strategies - Leukemia cells have mul
resistance by CHK1 inhibition with a novel agent
Treatment Strategies - Leukemia CDC25’s.59 Our
Treatment Strategies - Leukemia Emerging clini
Treatment Strategies - Leukemia of AZD7762 in
Treatment Strategies - Leukemia Chronic Lym
Treatment Strategies - Leukemia other Src fami
chain reaction.58 Furthermore, growth- and surviv
Treatment Strategies - Leukemia clones then be
leukaemia cells in vitro. British journal of haem
Treatment Strategies - Leukemia Leukemia B Ce
Treatment Strategies - Leukemia Clinical De
Treatment Strategies - Leukemia Eleven CLL pat
isoform of PI3K.26 SAR245408 (S08) is a class I p
Treatment Strategies - Leukemia preliminary st
engagement and phosphoinositide 3-kinase activati
MOST PATIENTS WITH MULTIPLE MYELOMA STILL
Treatment Strategies - Multiple Myeloma The
Treatment Strategies - Multiple Myeloma treatm
Treatment Strategies - Multiple Myeloma vorino
Treatment Strategies - Multiple Myeloma 3. Pei
Treatment Strategies - Multiple Myeloma New
Treatment Strategies - Multiple Myeloma highes
very good partial response or better in 17% and 2
Treatment Strategies - Multiple Myeloma Phase
Treatment Strategies - Multiple Myeloma 20. Pe
Treatment Strategies - Non-Hodgkin Lymphomas
enriched for ABC DLBCLs (Fisher exact test, p=0.0
Treatment Strategies - Non-Hodgkin Lymphomas p
70%.41 Additional reports from this and other ran
Treatment Strategies - Non-Hodgkin Lymphomas c
Treatment Strategies - Non-Hodgkin Lymphomas 3
Treatment Strategies - Paroxysmal Nocturnal Hemog
Treatment Strategies - Paroxysmal Nocturnal Hemog
Treatment Strategies - Paroxysmal Nocturnal Hemog
Treatment Strategies - Paroxysmal Nocturnal Hemog
Treatment Strategies - Paroxysmal Nocturnal Hemog
Treatment Strategies - Relapsed/Refractory AML
Treatment Strategies - Relapsed/Refractory AML
Achievement of CR2, however, significantly improv
Treatment Strategies - Relapsed/Refractory AML
had no adverse prognostic factors with AML had an
Treatment Strategies - Relapsed/Refractory AML
Treatment Strategies - Thrombosis Anticoagu
Treatment Strategies - Thrombosis benign proce
Treatment Strategies - Thrombosis Conclusions I
Treatment Strategies - Von Willebrand Disease
Author (yr) 6VWD No. Pregnancies No. Postpart
Treatment Strategies - Von Willebrand Disease V
Treatment Strategies - Von Willebrand Disease
Treatment Strategies - Von Willebrand Disease
FDA approves simplified ZEVALIN treatment. RITUXI
ZEVALIN® (ibritumomab tiuxetan) for Intravenous I
Severe Hematologic Toxicity in Patients Receiving
Treatment Strategies - Events Listings Up
e rsttPaatiteiennt tanadndCaCraerer an
Treatment Strategies - Events Listings American
The Cambridge Research Centre Coppergate House 16